IL312217A - STAGGERED TRIPLE NUCLEIC ACID COMPOUNDS - Google Patents

STAGGERED TRIPLE NUCLEIC ACID COMPOUNDS

Info

Publication number
IL312217A
IL312217A IL312217A IL31221724A IL312217A IL 312217 A IL312217 A IL 312217A IL 312217 A IL312217 A IL 312217A IL 31221724 A IL31221724 A IL 31221724A IL 312217 A IL312217 A IL 312217A
Authority
IL
Israel
Prior art keywords
lipid
nucleic acid
acid compounds
modified nucleic
triple
Prior art date
Application number
IL312217A
Other languages
English (en)
Hebrew (he)
Inventor
Charles Allerson
Arthur T Suckow
Original Assignee
Novartis Ag
Charles Allerson
Arthur T Suckow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Charles Allerson, Arthur T Suckow filed Critical Novartis Ag
Publication of IL312217A publication Critical patent/IL312217A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
IL312217A 2021-11-15 2022-11-14 STAGGERED TRIPLE NUCLEIC ACID COMPOUNDS IL312217A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163279270P 2021-11-15 2021-11-15
PCT/US2022/079790 WO2023086979A1 (en) 2021-11-15 2022-11-14 Staggered triple lipid-modified nucleic acid compounds

Publications (1)

Publication Number Publication Date
IL312217A true IL312217A (en) 2024-06-01

Family

ID=86336682

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312217A IL312217A (en) 2021-11-15 2022-11-14 STAGGERED TRIPLE NUCLEIC ACID COMPOUNDS

Country Status (10)

Country Link
US (1) US20250027082A1 (cg-RX-API-DMAC10.html)
EP (1) EP4433064A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024543372A (cg-RX-API-DMAC10.html)
KR (1) KR20240103016A (cg-RX-API-DMAC10.html)
CN (1) CN118215484A (cg-RX-API-DMAC10.html)
AU (1) AU2022387688A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235447A1 (cg-RX-API-DMAC10.html)
IL (1) IL312217A (cg-RX-API-DMAC10.html)
MX (1) MX2024005742A (cg-RX-API-DMAC10.html)
WO (1) WO2023086979A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026163078A1 (en) 2025-01-29 2026-08-06 Novartis Ag Compounds targeting dmpk for the treatment of myotonic dystrophy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7583712B2 (ja) * 2018-05-30 2024-11-14 ノバルティス アーゲー 脂質修飾された核酸化合物および方法
JP2023503644A (ja) * 2019-11-27 2023-01-31 ディー・ティー・エックス・ファーマ・インコーポレイテッド デュシェンヌ型筋ジストロフィーの治療のための化合物および方法

Also Published As

Publication number Publication date
US20250027082A1 (en) 2025-01-23
CN118215484A (zh) 2024-06-18
JP2024543372A (ja) 2024-11-21
MX2024005742A (es) 2024-05-27
EP4433064A4 (en) 2026-07-22
KR20240103016A (ko) 2024-07-03
AU2022387688A1 (en) 2024-04-11
CA3235447A1 (en) 2023-05-19
EP4433064A1 (en) 2024-09-25
WO2023086979A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
IL287468A (en) Nucleic acid constructs and methods for their manufacture
EP4116421A4 (en) Self-circularized rna structure
IL304334A (en) Modified double stranded oligonucleotides
IL309953A (en) Safer psychoactive compositions
EP3987019A4 (en) Barcode-based nucleic acid sequence assembly
DK4165024T3 (da) Cyclobutyldihydroquinolinsulfonamid-forbindelser
PL3838888T3 (pl) Triestry kwasu cykloheksanotripropionowego
IL283775A (en) Double-stranded nucleic acid inhibitor molecules containing a triloop
IL310528A (en) Pyrazolopyridinone compounds
IL287706A (en) Methods for detecting nucleic acid variants
JP1722049S (ja) サンダル
EP4149556C0 (en) PEG LIPIDOIDS COMPOUNDS
EP3773609A4 (en) TM-ENHANCING NUCLEOTIDES MODIFIED, DOUBLE STRANDED NUCLEIC ACID INHIBITOR MOLECULES
IL309943A (en) Signal activatable nucleic acid complexes
EP4006031A4 (en) DIHYDRO-PYRROLO-PYRIMIDINE SELECTIVE JAK2 INHIBITOR
DK4320112T3 (da) Pyridinylsubstituerede oxoisoindolinforbindelser
EP4419666A4 (en) METHYLATION ASSAYS OF ENCODED NUCLEIC ACIDS
IL318227A (en) Nucleic acid compounds
IL318225A (en) Nucleic acid compounds
EP4153751A4 (en) Oligonucleotides
EP4143199C0 (en) NUCLEOTIDE PROMEDICINAL COMPOUNDS
EP4209597C0 (en) NUCLEIC ACID SEQUENCING PROCESS
EP3377512A4 (en) Nucleic Acid PRODRUGS
EP3670630C0 (en) NEW ALKYLSULFONIC ACID COMPOSITIONS
EP4032551A4 (en) NUCLEIC ACID COMPLEX